This series of 4 podcasts will include discussions with expert leaders in melanoma. The content will focus on evaluating the use of immune checkpoint inhibitors in Stage II, Stage III, and Stage IV melanoma, understanding and overcoming resistance to anti- programmed cell death protein 1 (PD-1) immunotherapy, advances in the treatment and outcomes of patients with brain metastases, and the use of adjuvant and neoadjuvant treatment approaches.
Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician
Claim This Podcastby Medscape
4 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
This series of 4 podcasts will include discussions with expert leaders in melanoma. The content will focus on evaluating the use of immune checkpoint inhibitors in Stage II, Stage III, and Stage IV melanoma, understanding and overcoming resistance to anti- programmed cell death protein 1 (PD-1) immunotherapy, advances in the treatment and outcomes of patients with brain metastases, and the use of adjuvant and neoadjuvant treatment approaches.
Language
🇺🇲
Publishing Since
8/19/2022
1 verified contact email on file for Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
September 23, 2022
Expert Opinion: Use of Adjuvant and Neoadjuvant Approaches in Patients With Stage III Melanoma
<p>Dr Davies hosts Dr Mitchell on Podcast #4 to discuss adjuvant and neoadjuvant treatment approaches for patients with melanoma.</p> <p>Credit available for this activity expires: 9/23/2023 </p> <p>Earn Credit / Learning Objectives & Disclosures: <a class="external-link" href= "https://www.medscape.org/viewarticle/980272?src=mkm_podcast_addon_980272" target="_blank" rel= "noopener">https://www.medscape.org/viewarticle/980272?src=mkm_podcast_addon_980272</a></p>
September 14, 2022
Advances in the Treatments and Outcomes for Patients With Melanoma With Brain Metastases
<div class="line number1 index0 alt2" data-bidi-marker="true"> <span class="NormalTextRun SCXW148418474 BCX0" data-ccp-charstyle= "normaltextrun" data-ccp-charstyle-defn= "{"ObjectId":"40d63ec9-4652-47fe-8695-1e7482004c86|181","ClassId":1073872969,"Properties":[469775450,"normaltextrun",201340122,"1",134233614,"true",469778129,"normaltextrun",335572020,"1",469778324,"Default Paragraph Font"]}"> Dr Davies hosts Dr</span> <span class= "NormalTextRun SpellingErrorV2Themed SCXW148418474 BCX0" data-ccp-charstyle="normaltextrun">Tawbi</span> <span class= "NormalTextRun SCXW148418474 BCX0" data-ccp-charstyle= "normaltextrun">in a podcast focused on</span> <span class= "NormalTextRun SCXW148418474 BCX0" data-ccp-charstyle= "normaltextrun">treatments for patients with</span> <span class= "NormalTextRun SCXW148418474 BCX0" data-ccp-charstyle= "normaltextrun">melanoma with</span> <span class= "NormalTextRun SCXW148418474 BCX0" data-ccp-charstyle= "normaltextrun">brain metastases</span><span class= "NormalTextRun SCXW148418474 BCX0" data-ccp-charstyle= "normaltextrun">.</span></div> <div class="line number2 index1 alt1" data-bidi-marker="true"> </div> <div class="line number3 index2 alt2" data-bidi-marker="true"> <code class="xml plain">Credit available for this activity expires: [09/14/23]</code></div> <div class="line number3 index2 alt2" data-bidi-marker="true"> </div> <div class="line number4 index3 alt1" data-bidi-marker="true"> <code class="xml plain">Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/viewarticle/[ArticleID]?src=mkm_podcast_series_[ArticleID]"> https://www.medscape.org/viewarticle/980050?src=mkm_podcast_series_980050</a></code></div>
August 31, 2022
Understanding and Overcoming Resistance to Anti-PD-1 Immunotherapy in Melanoma
<p>Michael Davies host<span data-ccp-parastyle="Body Text">s</span> a series of 4 podcasts with leading experts to discuss important topics in melanoma<span data-ccp-parastyle= "Body Text">.</span><span data-ccp-props= "{"201341983":0,"335559739":120,"335559740":240}"> </span></p> <p>Credit available for this activity expires: 08/31/23</p> <p><span data-ccp-props= "{"201341983":0,"335559739":120,"335559740":240}"> Earn Credit / Learning Objectives & Disclosures: <a href= "https://www.medscape.org/viewarticle/%5bArticleID%5d?src=mkm_podcast_series_%5bArticleID%5d"> https://www.medscape.org/viewarticle/979092?src=mkm_podcast_series_979092</a></span></p>
4 total episodes available
Deep-dive analytics for Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.